Dr. Dixit is a Vice Preseident (R &D) & Global Head of Biologics Safety Assessment, Pathology, and Laboratory Animal Medicine. At MedImmune, an AstraZeneca Biologics R &D company. In his current position as a Vice President of R &D, and Global Head of Biologics Safety Assessment, including toxicology, pathology and LAR, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines. Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings.

Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications.. Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.

Appearances:

﻿

DC Co-conference Day 2 April 4 @ 09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40

Understanding the pathways used to create immune suppression and techniques to slow down immune suppression

What makes t-cell agonists so hard to work with vs checkpoint inhibitors?

Dr. Dixit is a Vice Preseident (R &D) & Global Head of Biologics Safety Assessment, Pathology, and Laboratory Animal Medicine. At MedImmune, an AstraZeneca Biologics R &D company. In his current position as a Vice President of R &D, and Global Head of Biologics Safety...

Dr Mark Cornfeld, VP, Immuno-Oncology Drug Development,Incyte

Mark Cornfeld MD/MPH is a board-certified oncologist with extensive experience in the development of novel and established therapies. Prior to joining industry he was a practicing hematologist/oncologist for more than a decade. He is currently VP of Immuno-Oncology at Incyte Corporation with...

Dr. Ching Ching Leow joined the Immuno-Oncology Clinical Development team at Lilly in January 2017 responsible for clinical development for a number of immunooncology programs. From 2008 to 2016 that she was a Medical Scientist and Translational lead at AstraZeneca responsible for conception and...